Cdk Inhibitors
Cdk Inhibitors - Related Videos
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
0 Views •
Cited by 4 •
2015
We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.
02:34
Inhibition of CDK Activity
0 Views •
2023
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34
Inhibition of Cdk Activity
0 Views •
2021
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:38
S-Cdk Initiates DNA Replication
0 Views •
2023
The cell cycle is a series of events leading to DNA duplication followed by the division of cell content to form two daughter cells. The cell cycle progresses in four stages—the cell increases in size (gap 1 or G1-phase), duplicates its DNA (synthesis or S-phase), prepares to divide (gap 2 or G2-phase), and divides (mitosis or M-phase). Two states at the origin of replication In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of replication.
02:15
M-Cdk Drives Transition Into Mitosis
0 Views •
2023
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system. Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase. M cyclin...
FAQs
Their effects arise through more than one molecular route. An inhibitor may bind directly to a cyclin-dependent kinase and reduce its catalytic activity, or it may disrupt the interaction between a CDK and its cyclin partner. Either mechanism lowers phosphorylation of proteins needed for cell-cycle progression, thereby limiting the downstream events required for continued advancement.
p21 and p27 function as endogenous regulators that help coordinate cell-cycle arrest. Their inhibitory activity links cell-cycle control to broader cellular conditions, including stress and developmental signals. By restraining CDK-dependent phosphorylation, these molecules can prevent progression when cellular circumstances call for a pause or when developmental coordination requires altered cell-cycle activity.
These mechanisms interfere with CDK function at different points. Direct catalytic inhibition targets the kinase activity responsible for phosphorylation, whereas disrupting CDK-cyclin interactions interferes with an essential regulatory partnership. Distinguishing the two is useful when interpreting how a molecule produces cell-cycle restraint and when relating the observed effect to the underlying control system.
Cellular stress and developmental signals are important contexts for endogenous inhibition. Under these conditions, proteins such as p21 and p27 help connect external or internal cues with cell-cycle arrest. This relationship makes CDK inhibition part of a broader decision-making system, rather than an isolated interruption of kinase activity.
Pharmacological inhibitors provide experimental tools for investigating cell-cycle control. Researchers can use them to restrict CDK activity and then examine the consequences for phosphorylation and cell-cycle progression. This approach helps distinguish the contribution of CDKs within cellular decisions and supports evaluation of how limiting their activity affects uncontrolled proliferation.
Uncontrolled proliferation is associated with disease contexts such as cancer, making CDK activity a relevant research focus. Pharmacological inhibitors can be evaluated for their ability to restrict this proliferation by limiting CDK-dependent processes. In biology, they therefore serve both as tools for studying abnormal cell-cycle regulation and as candidates for assessing treatments that impose proliferative restraint.